Riding the Femtech Wave: Why Progyny is a Key Stock for Investors to Track

2 min read

The stock price of Progyny (NASDAQ: PGNY), a femtech firm that specializes in fertility and family building benefits solutions, has enjoyed significant growth since its October 2019 listing – showing that the digital women’s health industry has grown into a formidable force in the wake of the Covid-19 pandemic.  Despite recent declining prices sparked in no small part by a director selling $327,285.70 in stock, Progyny was awarded an average ‘buy’ rating by the 10 brokerages covering the stock.  Many analysts have scrutinized PGNY shares in recent months. Jefferies Financial Group started coverage on Progyny in a research role in…...

This article is free to read

Login to read the full article


By subscribing to our main site, you will also be subscribed to DDIntel - our regular letter showcasing our featured articles and applications.

Dmytro Spilka Dmytro is a tech and finance writer based in London. His work has been published in Nasdaq, Kiplinger, Financial Express, The Diplomat, IBM, Investment Week and FXStreet.